TY - JOUR T1 - REG endpoint validation: Do database asthma control measures predict future risk? JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P3022 AU - Guy Brusselle AU - Richard J. Martin AU - Annie Burden AU - Alexandra Dima AU - Emilio Pizzichini AU - Janet Holbrook AU - Nikolaos G. Papadopoulos AU - Todor Popov AU - Gene Colice AU - Helen K. Reddel AU - Julie von Ziegenweidt AU - Alison Chisholm AU - David Price Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P3022.abstract N2 - Aim: Improved understanding of patient characteristics associated with exacerbations (EXBs) may provide opportunity to minimize future risk. We assessed whether database asthma control can predict future EXBs.Methods: Used a research database to select clinical records of patients aged 18–60yrs with an asthma diagnosis, continuous records over 1 baseline & 1 outcome yr and no other chronic respiratory disease or maintenance oral steroids. Two baseline control measures were evaluated: risk domain asthma control (RDAC) & overall control (OAC). RDAC was absence of: exacerbations, unplanned asthma-related out patient appointments, and antibiotics with evidence of respiratory review (ABX). OAC was: RDAC+average salbutamol ≤200µg/day. RDAC/OAC components predictive of outcome EXBs in univariable models were entered into a multivariable model and stepwise reduced. EXBs were: oral steroid courses with evidence of respiratory review (OS), asthma-related hospital admission or emergency room [ER] attendance.Results: Of 1558 patients (60% female), 73% and 42% satisfied criteria for RDAC and OAC control, respectively, at baseline.View this table:Baseline Predictors of EXB riskConclusions: Classification as RDAC or OAC at baseline predicted lower EXB rates in the following year. OS, ABX and asthma-related ER attendance independently predicted increased EXB risk regardless of “current control” as indicated by salbutamol use. ER -